The Impact of Concomitant Metabolic Syndrome in Patients with Schizophrenia on Clinical Dynamics and Social Adaptation

Abstract

Purpose: Studing the effect of metabolic disorders on the dynamics of schizophrenia and the development of social changes in patients with schizophrenia with concomitant MS.
Materials and methods. The study included 150 patients with schizophrenia with a verified diagnosis of schizophrenia according to ICDP10, undergoing inpatient treatment at the clinic of
the Mental Health Research Institute. All patients receive basic therapy using conventional and atypical antipsychotic drugs at recommended therapeutic doses for 6 weeks. Measurements
of morbidity, blood pressure and biochemical indicators were used to reliably diagnose IDF metabolic syndromes. Patients’ adaptive capacities are assessed using the social adaptation selfP
assessment scale (SSAS). The scale of positive and negative syndromes (PANSS) was used to assess the clinical manifestations of schizophrenia.
Results. According to the results of the assessment of social adaptation, it was revealed that there were no differences between the subgroups of patients. According to the results of
psychometric assessment of the dynamics of clinical symptoms in patients with schizophrenia and the accompanying metabolic syndrome, lower rates of reduction of positive and negative
symptoms in the process of antipsychotic therapy were revealed.
Conclusion. Metabolic syndrome is a complex of concomitant somatic disorders that aggravate the clinical manifestations of schizophrenia and adversely affect the effectiveness of
psychopharmacotherapy. Probably, the presence of metabolic syndrome does not adversely affect the level of social adaptation of patients.